$14.80
-0.01 (-0.07%)
Open$14.96
Previous Close$14.81
Day High$15.50
Day Low$14.50
52W High$15.84
52W Low$5.06
Volume—
Avg Volume213.0K
Market Cap201.60M
P/E Ratio—
EPS$-5.42
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+66.8% upside
Current
$14.80
$14.80
Target
$24.69
$24.69
$14.59
$24.69 avg
$25.91
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.96M | 11.88M | 13.51M |
| Net Income | 575.0K | 486.8K | 473.9K |
| Profit Margin | 4.4% | 4.1% | 3.5% |
| EBITDA | 905.5K | 814.6K | 969.2K |
| Free Cash Flow | 454.1K | 555.8K | 696.0K |
| Rev Growth | -0.8% | +15.7% | +3.2% |
| Debt/Equity | 0.71 | 1.01 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $261.07 | +3.99% | 126.9 | 461.26B |
| AMGN | Amgen Inc | $374.15 | +3.55% | 25.9 | 201.93B |
| GILD | Gilead Sciences Inc | $131.27 | +4.21% | 17.7 | 162.98B |
| VRTX | Vertex Pharmaceuticals Inc | $528.04 | +6.03% | 30.4 | 131.79B |
| REGN | Regeneron Pharmaceuticals | $654.27 | +4.73% | 15.5 | 68.59B |
| ALNY | Alnylam Pharmaceuticals Inc | $312.78 | +3.68% | 72.4 | 41.76B |